CAPTRUST Financial Advisors’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $10.9M | Buy |
34,607
+4,707
| +16% | +$1.11M | 0.02% | 550 |
|
|
2026
Q1 | $5.97M | Buy |
29,900
+15,321
| +105% | +$3.03M | 0.01% | 700 |
|
|
2025
Q4 | $2.76M | Sell |
14,579
-430
| -3% | -$82.6K | 0.01% | 931 |
|
|
2025
Q3 | $2.66M | Sell |
15,009
-600
| -4% | -$89.2K | 0.01% | 887 |
|
|
2025
Q2 | $1.77M | Buy |
15,609
+3,767
| +32% | +$403K | ﹤0.01% | 1031 |
|
|
2025
Q1 | $1.25M | Sell |
11,842
-192
| -2% | -$21.7K | ﹤0.01% | 1148 |
|
|
2024
Q4 | $1.29M | Sell |
12,034
-188
| -2% | -$21.3K | ﹤0.01% | 1099 |
|
|
2024
Q3 | $1.22M | Sell |
12,222
-407
| -3% | -$41K | ﹤0.01% | 1072 |
|
|
2024
Q2 | $1.06M | Buy |
12,629
+5,912
| +88% | +$470K | ﹤0.01% | 1103 |
|
|
2024
Q1 | $491K | Buy |
6,717
+402
| +6% | +$29.6K | ﹤0.01% | 1491 |
|
|
2023
Q4 | $451K | Buy |
6,315
+330
| +6% | +$19.5K | ﹤0.01% | 1805 |
|
|
2023
Q3 | $359K | Buy |
+5,985
| New | +$394K | ﹤0.01% | 1882 |
|
|
2022
Q3 | – | Sell |
-1,446
| Closed | -$80K | – | 3162 |
|
|
2022
Q2 | $80K | Buy |
1,446
+16
| +1% | +$908 | ﹤0.01% | 2376 |
|
|
2022
Q1 | $100K | Sell |
1,430
-713
| -33% | -$51.7K | ﹤0.01% | 2264 |
|
|
2021
Q4 | $207K | Sell |
2,143
-276
| -11% | -$25.5K | ﹤0.01% | 1614 |
|
|
2021
Q3 | $210K | Buy |
2,419
+56
| +2% | +$4.33K | ﹤0.01% | 1527 |
|
|
2021
Q2 | $193K | Sell |
2,363
-1
| -0% | -$83 | ﹤0.01% | 1548 |
|
|
2021
Q1 | $225K | Buy |
2,364
+2,175
| +1,151% | +$206K | ﹤0.01% | 1390 |
|
|
2020
Q4 | $12K | Buy |
189
+8
| +4% | +$456 | ﹤0.01% | 2484 |
|
|
2020
Q3 | $11K | Sell |
181
-754
| -81% | -$51.4K | ﹤0.01% | 2243 |
|
|
2020
Q2 | $65K | Sell |
935
-1,681
| -64% | -$107K | ﹤0.01% | 1520 |
|
|
2020
Q1 | $111K | Buy |
+2,616
| New | +$148K | ﹤0.01% | 1078 |
|
|
2019
Q4 | – | Sell |
-596
| Closed | -$37K | – | 1450 |
|
|
2019
Q3 | $37K | Hold |
596
| – | – | ﹤0.01% | 1093 |
|
|
2019
Q2 | $42K | Buy |
596
+64
| +12% | +$4.71K | ﹤0.01% | 1036 |
|
|
2019
Q1 | $42K | Buy |
532
+399
| +300% | +$30.2K | ﹤0.01% | 959 |
|
|
2018
Q4 | $11K | Hold |
133
| – | – | ﹤0.01% | 1204 |
|
|
2018
Q3 | $23K | Buy |
133
+128
| +2,560% | +$19.3K | ﹤0.01% | 957 |
|
|
2018
Q2 | $1K | Sell |
5
-9
| -64% | -$1K | ﹤0.01% | 1457 |
|
|
2018
Q1 | $1K | Buy |
+14
| New | +$1.39K | ﹤0.01% | 1281 |
|
Other funds holding LGND
JT
CAM
CAPTRUST Financial Advisors's LGND Position: Q2 2026 in Review
CAPTRUST Financial Advisors increased its Ligand Pharmaceuticals (LGND) stake by 16% in Q2 2026, buying an estimated $1.11M and bringing the position to 34,607 shares worth $10.9M. The position accounts for 0.02% of the portfolio, ranked #550.
CAPTRUST Financial Advisors first reported a position in LGND in Q1 2018 and has held it in 29 quarters since. 417 funds tracked by Wall St. Rank hold LGND as of Q2 2026.
- CAPTRUST Financial Advisors held 34,607 shares of Ligand Pharmaceuticals worth $10.9M as of Q2 2026.
- CAPTRUST Financial Advisors bought 4,707 Ligand Pharmaceuticals shares in Q2 2026, an estimated $1.11M.
- Ligand Pharmaceuticals made up 0.02% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #550 holding.
- CAPTRUST Financial Advisors first reported a position in Ligand Pharmaceuticals in Q1 2018 and has held it in 29 quarters since.
- 417 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.